Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.

Diabetes Mellitus Clinical Trial

Official title:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Insulin in Subjects With Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00286429
• Other study ID #: SYR-322-INS-011
• Secondary ID: 2005-004671-38U1
• Status: Completed
• Phase: Phase 3
• First received: February 1, 2006
• Last updated: February 1, 2012
• Start date: February 2006
• Est. completion date: May 2007

Study information

• Verified date: February 2012
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of alogliptin, once daily (QD), taken in combination with insulin for the treatment of Type 2 Diabetes.

Description:

There are approximately 19 million people in the United States who have been diagnosed with diabetes mellitus, of which 90% to 95% are type 2. The prevalence of type 2 diabetes varies among racial and ethnic populations and has been shown to correlate with age, obesity, family history, history of gestational diabetes, and physical inactivity. Over the next decade, a marked increase in the number of adults with diabetes mellitus is expected.

Takeda is developing alogliptin (SYR-322) for patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV enzyme. Dipeptidyl peptidase IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of dipeptidyl peptidase IV will improve glycemic (glucose) control in patients with type 2 diabetes.

The aim of the current study is to evaluate the efficacy of alogliptin in combination with insulin in subjects who are inadequately controlled on insulin alone (with or without metformin). Individuals who participate in this study will be required to commit to a screening visit and up to 14 additional visits at the study center. Study participation is anticipated to be about 34 weeks (or 8.5 months).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 390
• Est. completion date: May 2007
• Est. primary completion date: May 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria

• Diagnosis of type 2 diabetes mellitus and currently treated with insulin alone (with or without metformin), and is inadequately controlled. Metformin dose must be stable for at least 8 weeks prior to Randomization.

• No treatment with antidiabetic agents other than insulin and metformin within the 8 weeks prior to Randomization.

• Body mass index greater than or equal to 23 kg/m2 and less than or equal to 45 kg/m2

• Fasting C-peptide concentration greater than or equal to 0.8 ng per mL. (If this screening criterion is not met, the subject still qualifies if C-peptide greater than or equal to 1.5 ng per mL after a challenge test).

• Glycosylated hemoglobin concentration greater than or equal to 8.0% at Screening.

• Using a stable dose of insulin of at least 15 units but not more than 100 units per day for at least 8 weeks prior to Randomization. A dose of insulin that varies by up to 15% of the mean will be considered as stable.

• If regular use of other, non-excluded medications, must be on a stable dose for at least the 4 weeks prior to Screening. However, as needed use of prescription or over-the-counter medications is allowed at the discretion of the investigator.

• Systolic blood pressure less than or equal to180 mm Hg and diastolic pressure less than or equal to 110 mm Hg

• Hemoglobin greater than or equal to 12 g per dL for males and greater than or equal to10 g per dL for females.

• Alanine aminotransferase less than or equal to 3 times the upper limit of normal.

• Serum creatinine less than or equal to 2.0 mg per dL.

• Thyroid-stimulating hormone level less than or equal to the upper limit of the normal range and the subject is clinically euthyroid.

• Neither pregnant (confirmed by laboratory testing in females of childbearing potential) nor lactating.

• Female subjects of childbearing potential must be practicing adequate contraception. Adequate contraception must be practiced for the duration of participation in the study.

• Able and willing to monitor own blood glucose concentrations with a home glucose monitor

• No major illness or debility that in the investigator's opinion prohibits the individual from completing the study

• Able and willing to provide written informed consent

Exclusion Criteria

• Urine albumin to creatinine ratio of greater than 1000 µg per mg at Screening. If elevated, the subject may be rescreened within 1 week.

• History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 5 years prior to Screening. (History of treated cervical intraepithelial neoplasia I or cervical intraepithelial neoplasia II is allowed.).

• History of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.

• History of treated diabetic gastric paresis.

• New York Heart Association Class III or IV heart failure regardless of therapy. Currently treated subjects who are stable at Class I or II are candidates for the study.

• History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 6 months prior to Screening.

• History of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.

• History of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.

• History of a psychiatric disorder that will affect ability to participate in the study.

• History of angioedema in association with use of angiotensin-converting enzyme inhibitors or angiotensin-II receptor inhibitors.

• History of alcohol or substance abuse within the 2 years prior to Screening.

• Receipt of any investigational drug within the 30 days prior to Screening or a history of receipt of an investigational antidiabetic drug within the 3 months prior to Screening.

• Prior treatment in an investigational study of alogliptin.

• Excluded Medications:

• Treatment with antidiabetic agents other than insulin and metformin is not allowed within the 8 weeks prior to Randomization and through the completion of the end-of treatment or early termination procedures. (Exception: if has received other antidiabetic therapy for less than 7 days within the 3 months prior to Screening.)

• Treatment with weight-loss drugs, any investigational antidiabetics, or oral or systemically injected glucocorticoids is not allowed from 3 months prior to randomization through the completion of the end-of-treatment or early termination procedures. Inhaled corticosteroids are allowed.

• Must not take any medications, including over-the-counter products, without first consulting with the investigator.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Drug:
• Alogliptin and insulin
Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
• Alogliptin and insulin
Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
• Insulin
Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Brazil,  Chile,  Czech Republic,  Germany,  Guatemala,  Hungary,  India,  Mexico,  Netherlands,  New Zealand,  Peru,  Poland,  South Africa, 

References & Publications (2)

Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009 Nov;57(11):2011-9. doi: 10.1111/j.1532-5415.2009.02484.x. Epub 2009 Sep 30. — View Citation

Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009 Dec;11(12):1145-52. do — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.	The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 26 or final visit and glycosylated hemoglobin collected at baseline.	Baseline and Week 26.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 4).	The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and Glycosylated Hemoglobin collected at baseline.	Baseline and Week 4.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 8).	The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and Glycosylated Hemoglobin collected at baseline.	Baseline and Week 8.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 12).	The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and Glycosylated Hemoglobin collected at baseline.	Baseline and Week 12.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 16).	The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and Glycosylated Hemoglobin collected at baseline.	Baseline and Week 16.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 20).	The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and Glycosylated Hemoglobin collected at baseline.	Baseline and Week 20.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 1).	The change between the value of fasting plasma glucose collected at final visit or week 1 and fasting plasma glucose collected at baseline.	Baseline and Week 1.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 2).	The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline.	Baseline and Week 2.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 4).	The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline.	Baseline and Week 4.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 8).	The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline.	Baseline and Week 8.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 12).	The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline.	Baseline and Week 12.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 16).	The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline.	Baseline and Week 16.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 20).	The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline.	Baseline and Week 20.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 26).	The change between the value of fasting plasma glucose collected at week 26 or final visit and fasting plasma glucose collected at baseline.	Baseline and Week 26.	No
Secondary	Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose = 200 mg Per dL).	The number of participants with a fasting plasma glucose value greater than or equal to 200 mg per dL during the 26 week study.	26 Weeks.	No
Secondary	Number of Participants Requiring Rescue.	The number of participants requiring rescue for failing to achieve pre-specified glycemic targets during the 26 week study.	26 Weeks.	No
Secondary	Change From Baseline in C-peptide (Week 4).	The change between the value of C-peptide collected at week 4 and C-peptide collected at baseline.	Baseline and Week 4.	No
Secondary	Change From Baseline in C-peptide (Week 8).	The change between the value of C-peptide collected at week 8 and C-peptide collected at baseline.	Baseline and Week 8.	No
Secondary	Change From Baseline in C-peptide (Week 12).	The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline.	Baseline and Week 12.	No
Secondary	Change From Baseline in C-peptide (Week 16).	The change between the value of C-peptide collected at week 16 and C-peptide collected at baseline.	Baseline and Week 16.	No
Secondary	Change From Baseline in C-peptide (Week 20).	The change between the value of C-peptide collected at week 20 and C-peptide collected at baseline.	Baseline and Week 20.	No
Secondary	Change From Baseline in C-peptide (Week 26).	The change between the value of C-peptide collected at week 26 or final visit and C-peptide collected at baseline.	Baseline and Week 26.	No
Secondary	Number of Participants With Glycosylated Hemoglobin = 6.5%.	The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 6.5% during the 26 week study.	Baseline and Week 26.	No
Secondary	Number of Participants With Glycosylated Hemoglobin = 7.0%.	The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.0% during the 26 week study.	Baseline and Week 26.	No
Secondary	Number of Participants With Glycosylated Hemoglobin = 7.5%.	The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.5% during the 26 week study.	Baseline and Week 26.	No
Secondary	Number of Participants With Glycosylated Hemoglobin Decrease From Baseline = 0.5%.	The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 0.5% during the 26 week study.	Baseline and Week 26.	No
Secondary	Number of Participants With Glycosylated Hemoglobin Decrease From Baseline = 1.0%.	The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.0% during the 26 week study.	Baseline and Week 26.	No
Secondary	Number of Participants With Glycosylated Hemoglobin Decrease From Baseline = 1.5%.	The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.5% during the 26 week study.	Baseline and Week 26.	No
Secondary	Number of Participants With Glycosylated Hemoglobin Decrease From Baseline = 2.0%.	The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 2.0% during the 26 week study.	Baseline and Week 26.	No
Secondary	Change From Baseline in Body Weight (Week 8).	The change between Body Weight measured at week 8 and Body Weight measured at baseline.	Baseline and Week 8.	No
Secondary	Change From Baseline in Body Weight (Week 12).	The change between Body Weight measured at week 12 and Body Weight measured at baseline.	Baseline and Week 12.	No
Secondary	Change From Baseline in Body Weight (Week 20).	The change between Body Weight measured at week 20 and Body Weight measured at baseline.	Baseline and Week 20.	No
Secondary	Change From Baseline in Body Weight (Week 26).	The change between Body Weight measured at week 26 or final visit and Body Weight measured at baseline.	Baseline and Week 26.	No